---
document_datetime: 2023-09-21 17:40:58
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/leukoscan-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: leukoscan-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.4274435
conversion_datetime: 2025-12-20 17:33:50.693892
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 1 October 2002 please refer to module 8B.

•

•

<!-- image -->

· The MAH submitted to the EMEA on 27 December 1996 an application for a Type I variation in  order  to  include  labelling  and  packaging  responsibility  of  the  finished  product  for  the following manufacturing site: Mallinckrodt Medical, B.V., Westerduinweg 3, 1755 ZG Petten, The Netherlands. The procedure started on 3 January 1997. The EMEA accepted the Variation and issued the relevant notification on 20 January 1997. This  variation  did  not  require  any amendment to the Community Marketing Authorisation. · The MAH submitted to the EMEA on 14 January 1997 an application for a Type I variation following a 60 days procedure to revise the isoelectric focusing specifications in the finished product  specifications.  The  procedure  started  on  24  January  1997.  The  CPMP  adopted  a positive  opinion  on  19  March  1997.  This  variation  did  not  require  any  amendment  to  the Community Marketing Authorisation. · The MAH submitted to the EMEA on 3 April 1997 an application for a Type I variation related to the extension of the shelf life of the product from 24 to 36 months at 2-8 o C. The procedure started on 20 June 1997. The EMEA accepted the Variation and issued the relevant notification on 14 July 1997. Annexes I and IIIB to the Community Marketing Authorisation were amended accordingly. · The MAH submitted to the EMEA on  17 December application for a Type I variation related to the change of the name and address of Immunomedics B.V., Westerduinweg 3, 1755 ZG Petten, The  Netherlands  to:  Immunomedics  Europe,  Haarlemmerstraat  30,  2181  HC  Hillegom  The Netherlands. The procedure started on 7 January 1998. The EMEA accepted the Variation and issued  the  relevant  notifications  on  15  January  1998.  Annexes  I,  IIIA  and  IIIB  to  the Community Marketing Authorisation were amended accordingly. · The MAH submitted to the EMEA on 24 November 1997 an application for a Type II variation to introduce a change of the manufacturing site from Newark, NJ to Morris Plains, NJ and two significant changes in the manufacturing process. The procedure started on 19 December 1997. The  CPMP  adopted  a  positive  opinion  on  27  May  1998.  This  variation  did  not  require  any amendment to the Community Marketing Authorisation. · The MAH submitted to the EMEA on  22 December an application for a Type I variation in order  to  change  the  manufacturer  responsible  for  import  into  EU  and  batch  release  of  the finished  product  from:  Mallinckrodt  Medical,  B.V.,  Westerduinweg  3,  1755  ZG  Petten,  The Netherland  to:  Eli  Lilly  Deutschland  GmbH,  Teichweg  3  D-35396  Geissen,  Germany. The procedure started on 5 January 1998. The EMEA accepted the Variation and issued the relevant notification  on  15  January  1998.  Annexes  I,  II  and  III  to  the  Community  Marketing Authorisation were amended accordingly. The MAH submitted to the EMEA on  19 March 1999 an  application  for  a  Type  I  variation related  to  the  extension  of  the  shelf  life  of  the  product  from  36  to  48  months  at  2-8ºC. The procedure started on 26 March 1999. The EMEA accepted the Variation and issued the relevant notification on 26 April 1999. Annexes I and IIIB to the Community Marketing Authorisation were amended accordingly. Medicinal product no longer authorised

- The MAH submitted to the EMEA on 19 March 1999 an application for a Type I variation in order to change the name of manufacturer responsible for import into EU and batch release in the  European  Economic  Area  from:  Eli  Lilly  Deutschland  GmbH,  to:  Eli  Lilly  Pharma Fertigung und Distribution GmbH &amp; Co. KG. The procedure started on 26 March 1999. The EMEA accepted the Variation and issued the relevant notification on 26 April 1999. Annexes I, II and III to the Community Marketing Authorisation were amended accordingly.

<div style=\"page-break-after: always\"></div>

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                       | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on   |
|---------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------------|
| Extension of shelf-life as foreseen at time of authorisation                                | I/0006               | I                        | 22.07.98                            | 15.04.99                                 |
| Extension of shelf life from 36 to 48 months                                                | I/0007               | I                        | 26.04.99                            | 18.06.99                                 |
| Change in the name of the manufacturer responsible for importation and batch release        | I/0008               | I                        | 26.04.99                            | 18.06.99                                 |
| Change in or addition of manufacturing site(s) for part or all of the manufacturing process | I/0009               | I                        | 06.08.99                            | 17.08.99                                 |
| Change in or addition of manufacturing site(s) for part or all of the manufacturing process | I/001I               | I                        | 06.09.00                            |                                          |
| Changes to comply with supplements to pharmacopoeias                                        | I/0012               | I                        | 15.02.01                            | 20.03.01                                 |
| Renewal                                                                                     | R/0013               | R                        | 21.02.02                            | 30.09.02                                 |
| Change in manufacturing authorisation                                                       | I/0015               | I                        | 08.05.02                            | 17.06.02                                 |
| Transfer of Marketing Authorisation Holder                                                  | T/0016               | T                        | 23.08.02                            | 18.09.02                                 |

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

Change in the name of the manufacturer responsible for importation and batch release Change in or addition of manufacturing site(s) for part or all of the manufacturing process Change in or addition of manufacturing site(s) for part or all of the manufacturing process Changes to comply with supplements to pharmacopoeias Renewal Change in manufacturing authorisation Transfer of Marketing Authorisation Holder 1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application. Medicinal product no longer authorised

N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.